- Home
- Results news
- Tatva Chintan Pharma Chem
- Q2 FY27 results
Tatva Chintan Pharma Chem Q2 FY27 results: net profit up 116.2% to ₹21.45 crore, revenue up 75.9%
Tatva Chintan Pharma Chem Limited reported consolidated Q2 FY27 revenue of ₹217.32 crore, up 75.9% from Q2 FY26, while net profit rose 116.2% to ₹21.45 crore. EBITDA increased 83.1% to ₹40.69 crore, but margin eased 0.6 percentage points sequentially to 18.7% as higher material and freight costs offset revenue growth.
Key points
- Revenue was ₹217.32 crore in Q2 FY27, up ₹93.80 crore or 75.9% from ₹123.52 crore in Q2 FY26.
- EBITDA was ₹40.69 crore, up 83.1% year on year, while EBITDA margin rose 0.7 percentage points to 18.7%.
- Net profit was ₹21.45 crore, up 116.2% year on year, and basic EPS rose to ₹9.17 from ₹4.24.
- Against Q1 FY27, revenue rose 30.1% to ₹217.32 crore and net profit rose 34.2% to ₹21.45 crore.
- For H1 FY27, revenue was ₹384.38 crore and net profit was ₹37.43 crore, up 59.9% and 125.9%, respectively, from H1 FY26.
How did Tatva Chintan Pharma Chem perform in Q2 FY27?
Tatva Chintan Pharma Chem reported consolidated revenue of ₹217.32 crore for Q2 FY27, up 75.9% from ₹123.52 crore in Q2 FY26 and 30.1% from ₹167.06 crore in Q1 FY27. EBITDA rose 83.1% year on year to ₹40.69 crore, while margin increased 0.7 percentage points to 18.7% from 18.0%. Sequentially, EBITDA was up 26.0% and margin fell 0.6 percentage points from 19.3%.
Profit before tax rose 111.9% year on year to ₹28.94 crore and 37.1% sequentially from ₹21.11 crore. Net profit increased 116.2% year on year to ₹21.45 crore from ₹9.92 crore and was up 34.2% from ₹15.98 crore in Q1 FY27. Basic EPS was ₹9.17, compared with ₹4.24 a year earlier and ₹6.83 in the previous quarter.
On the standalone basis, revenue was ₹207.48 crore, up 79.1% from the year-ago period, while net profit before tax was ₹8.94 crore and profit after tax was ₹15.39 crore. The Board approved the standalone and consolidated unaudited results for the quarter and half year ended 30 September 2026 after the Audit Committee reviewed and recommended them.
| ₹ crore | Q2 FY27 | Q1 FY27 | Q2 FY26 | YoY | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 217.32 | 167.06 | 123.52 | +75.9% | +30.1% |
| Other income | 1.75 | 2.78 | 1.01 | +73.3% | −37.1% |
| Total expenses | 190.13 | 147.41 | 110.86 | +71.5% | +29.0% |
| EBITDA | 40.69 | 32.30 | 22.22 | +83.1% | +26.0% |
| EBITDA margin | 18.7% | 19.3% | 18.0% | +0.7 pp | −0.6 pp |
| Profit before tax | 28.94 | 21.11 | 13.66 | +111.9% | +37.1% |
| Tax | 7.49 | 5.13 | 3.75 | +99.7% | +46.0% |
| Net profit | 21.45 | 15.98 | 9.92 | +116.2% | +34.2% |
| EPS (₹) | 9.17 | 6.83 | 4.24 | +116.3% | +34.3% |
EBITDA here is revenue from operations less operating costs (total expenses excluding finance costs and depreciation): before other income and exceptional items. Growth is shown only when both figures are positive. Source: Company's results filing (XBRL).
What changed in Tatva Chintan Pharma Chem's costs and profit?
Total expenses rose 71.5% year on year to ₹190.13 crore. Cost of materials increased ₹52.06 crore, or 84.0%, to ₹114.05 crore, while other expenses rose ₹20.66 crore, or 65.6%, to ₹52.15 crore. Employee cost increased 21.9% to ₹18.23 crore, finance costs rose 431.4% to ₹2.71 crore, and depreciation rose 19.2% to ₹10.79 crore.
Other income increased 73.3% year on year to ₹1.75 crore from ₹1.01 crore, while tax expense rose 99.7% to ₹7.49 crore from ₹3.75 crore. There was no exceptional item in Q2 FY27, compared with an exceptional charge of ₹1.32 crore in Q1 FY27. Management said solvent prices increased by 60%-100% amid erratic short supplies and global freight rose by more than 100% in certain US and Europe sectors, weighing on margins.
Sequentially, total expenses rose 29.0% to ₹190.13 crore and cost of materials increased 8.2% to ₹114.05 crore. Other expenses rose 22.0% to ₹52.15 crore, employee cost increased 8.9% to ₹18.23 crore, and finance costs rose 30.3% to ₹2.71 crore. Other income fell 37.1% to ₹1.75 crore, while tax expense rose 46.0% to ₹7.49 crore.
| ₹ crore | Q2 FY27 | Q2 FY26 | Change | Change % |
|---|---|---|---|---|
| Cost of materials | 114.05 | 61.99 | +52.06 | +84.0% |
| Employee cost | 18.23 | 14.95 | +3.28 | +21.9% |
| Finance costs | 2.71 | 0.51 | +2.20 | +431.4% |
| Depreciation | 10.79 | 9.05 | +1.74 | +19.2% |
| Other expenses | 52.15 | 31.49 | +20.66 | +65.6% |
| Total expenses | 190.13 | 110.86 | +79.27 | +71.5% |
| Other income | 1.75 | 1.01 | +0.74 | +73.3% |
| Tax | 7.49 | 3.75 | +3.74 | +99.7% |
Source: Company's results filing (XBRL).
How did the first half of FY27 go?
For the first half of FY27, consolidated revenue was ₹384.38 crore, up ₹144.0 crore or 59.9% from ₹240.38 crore in H1 FY26. Total income rose 60.3% to ₹388.91 crore, while profit before tax increased 119.9% to ₹50.05 crore from ₹22.76 crore.
Net profit for H1 FY27 was ₹37.43 crore, up ₹20.86 crore or 125.9% from ₹16.57 crore in the year-ago first half. Basic EPS increased 126.0% to ₹16.00 from ₹7.08. The consolidated results for the half year ended 30 September 2026 were unaudited and approved by the Board on 19 October 2026.
| ₹ crore | H1 FY27 | H1 FY26 | Change |
|---|---|---|---|
| Revenue from operations | 384.38 | 240.38 | +59.9% |
| Profit before tax | 50.05 | 22.76 | +119.9% |
| Net profit | 37.43 | 16.57 | +125.9% |
| EPS (₹) | 16.00 | 7.08 | +126.0% |
Source: Company's results filing (XBRL).
What do the balance sheet and cash flow show?
Total assets increased to ₹1118.73 crore at 30 September 2026 from ₹1003.69 crore at 31 March 2026. Total equity rose to ₹814.65 crore from ₹781.76 crore, borrowings increased to ₹170.0 crore from ₹120.37 crore, and cash rose to ₹10.68 crore from ₹5.76 crore. Inventories increased to ₹248.91 crore from ₹196.07 crore, trade receivables to ₹178.38 crore from ₹119.03 crore, and trade payables to ₹85.52 crore from ₹58.25 crore.
For H1 FY27, operating cash flow was negative ₹3.68 crore, compared with positive ₹13.38 crore in H1 FY26. Investing cash flow was negative ₹31.34 crore against negative ₹57.78 crore, while financing cash flow was positive ₹39.96 crore against positive ₹45.73 crore. Capital expenditure was ₹30.84 crore, compared with ₹56.0 crore in the year-ago period.
| ₹ crore | As of 30 September 2026 | As of 31 March 2026 |
|---|---|---|
| Total assets | 1,119 | 1,004 |
| Total equity | 814.65 | 781.76 |
| Borrowings | 170 | 120.37 |
| Cash and equivalents | 10.68 | 5.76 |
| Inventories | 248.91 | 196.07 |
| Trade receivables | 178.38 | 119.03 |
Source: Company's results filing (XBRL).
| ₹ crore | H1 FY27 | H1 FY26 |
|---|---|---|
| Cash from operations | −3.68 | 13.38 |
| Cash from investing | −31.34 | −57.78 |
| Cash from financing | 39.96 | 45.73 |
| Capital expenditure | 30.84 | 56 |
Source: Company's results filing (XBRL).
How has Tatva Chintan Pharma Chem done over the last 8 quarters?
Revenue rose in each of the last eight quarters on a year-on-year basis, while profit rose year on year in each of the last four quarters. Revenue increased from ₹85.9 crore in Q3 FY25 to ₹217.32 crore in Q2 FY27, while profit moved from ₹0.14 crore to ₹21.45 crore over the same period.
Profit peaked at ₹21.45 crore in Q2 FY27, while the EBITDA margin bottomed at 8.2% in Q3 FY25 and peaked at 21.0% in Q4 FY26. Revenue and profit both increased in Q2 FY27, but EBITDA margin declined from 19.3% in Q1 FY27 to 18.7%.
What else did the company announce?
Tatva Chintan Pharma Chem filed an investor presentation for the quarter and half year ended 30 September 2026 on 19 October 2026. The company subsequently filed a revised presentation to correct typographical errors on page 12; it stated that there were no changes to the other financial numbers in the presentation. No dividend, fund raise or appointment was reported in the same-day filings.
The revised presentation changed the H1 FY27 RoE figure to 6.3% from 2.6% and the debt-to-EBITDA figure to 1.16x from 4.30x. The company said the debt-to-EBITDA measure was an annualised figure and that it had taken steps to prevent recurrence of the errors.
What did Tatva Chintan Pharma Chem's management say?
Management said it expected solvent and freight costs to normalise in Q3 FY27 and foresaw revenue growth continuing with similar momentum over the next quarters, with EBITDA margin returning to its healthy trajectory. It said the company’s priorities were to sustain revenue momentum and ensure that growth translated into sustainable profits.
Management said EURO 7 emission standards were contributing to sales of Structured Directing Agents. It also said hybrid-battery applications were progressing towards commercialisation, all five semiconductor chemical products were advancing through development, validation and customer qualification, and the new greenfield project was progressing according to its planned schedule.
Management identified cost movements, progressive customer pricing and careful investment execution as financial-discipline priorities. The presentation also noted export dependence of 75% of FY26 revenue across more than 30 countries, creating geopolitical and trade-policy exposure. No analyst questions were included in the filing excerpts.
How did Tatva Chintan Pharma Chem shares react?
After the filing appeared after market hours, the stock was down 1.8% after 5 minutes, 1.8% after 15 minutes and 3.0% after 30 minutes. It closed the reaction session down 3.9% from its pre-results close, against a 3.3% median decline for other Specialty Chemicals stocks.
By the next day's close, the stock was down 14.1% from its pre-results close, compared with a 4.3% median decline for the industry. By the fifth session, it was down 14.6%, versus a 5.3% industry decline. The stock underperformed the industry median by 9.7 percentage points on the next day and 9.3 percentage points over five sessions.
Earlier reaction-day moves were mixed: the stock rose 19.8% on 17 July 2026, fell 6.4% on 16 May 2026 and 8.8% on 21 January 2026, and rose 11.3% on 24 July 2025. The reaction-day decline for this result was 3.9%.
| After the filing | Stock | Specialty Chemicals median |
|---|---|---|
| 5 minutes | −1.8% | |
| 15 minutes | −1.8% | |
| 30 minutes | −3.0% | |
| Reaction day | −3.9% | −3.3% |
| Next day | −14.1% | −4.3% |
| 5 days | −14.6% | −5.3% |
Minutes are measured from the price when the filing appeared; days from the previous close. Source: MarketPing price-reaction measurement.
| Results filed on | Stock on the reaction day |
|---|---|
| 17 July 2026 | +19.8% |
| 16 May 2026 | −6.4% |
| 21 January 2026 | −8.8% |
| 31 October 2025 | −1.5% |
| 24 July 2025 | +11.3% |
| 2 May 2025 | +3.0% |
| 28 January 2025 | −4.1% |
| 25 October 2024 | −11.7% |
Source: MarketPing price-reaction measurement.
How did other Specialty Chemicals companies do?
A total of 51 Specialty Chemicals companies were compared for the quarter. Their median revenue growth was 28.1%, compared with Tatva Chintan Pharma Chem’s 75.9% consolidated revenue growth. Of the other companies, 43 grew slower than Tatva Chintan Pharma Chem and 8 grew faster than Tatva Chintan Pharma Chem.
Of the 47 peers for which profit was compared, 41 reported higher profit. The peer data was available as of 4 November 2026, while Tatva Chintan Pharma Chem’s result was announced on 19 October 2026.
| Tatva Chintan Pharma Chem revenue growth (YoY) | +75.9% |
|---|---|
| Median of 51 other Specialty Chemicals companies | +28.1% |
| Companies with slower revenue growth than Tatva Chintan Pharma Chem | 43 of 51 |
| Companies with faster revenue growth than Tatva Chintan Pharma Chem | 8 of 51 |
| Companies whose net profit rose | 41 of 47 |
Source: Filed results (XBRL) of the industry's companies.
Quick answers
What was Tatva Chintan Pharma Chem's revenue in Q2 FY27?
Revenue from operations was ₹217.32 crore, up 75.9% from ₹123.52 crore in Q2 FY26 (consolidated).
Did Tatva Chintan Pharma Chem make a profit in Q2 FY27?
Yes. Net profit was ₹21.45 crore, against a net profit of ₹9.92 crore in Q2 FY26.
What was Tatva Chintan Pharma Chem's EPS in Q2 FY27?
Basic earnings per share were ₹9.17, against ₹4.24 in Q2 FY26.
How did Tatva Chintan Pharma Chem shares react to the Q2 FY27 results?
On the reaction day the stock moved −3.9% from the previous close; the median Specialty Chemicals stock moved −3.3%.
When did Tatva Chintan Pharma Chem announce its Q2 FY27 results?
On 19 October 2026, in a filing to the NSE.
Sources
- Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday, 19.10.2026 (BSE, 12 October 2026) · PDF
- Outcome of Board Meeting (NSE, 19 October 2026) · PDF
- The investor presentation (19 October 2026)
How this was written: every figure in the tables and charts is calculated from the company’s filed results (XBRL) and MarketPing’s price measurements. The text is drafted with AI from those figures and the filings, and a checker removes any sentence carrying a number it cannot trace to them. How we write these.
This is information, not investment advice. MarketPing does not recommend buying or selling any security.